Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Cash & Equivalents (2016 - 2025)

PAVmed has reported Cash & Equivalents over the past 6 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 26.58% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 26.58%, while the annual FY2025 figure was $1.5 million, 26.58% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $1.5 million at PAVmed, down from $3.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $77.3 million in Q4 2021 and troughed at $1.2 million in Q4 2024.
  • A 5-year average of $32.3 million and a median of $31.8 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 347.72% in 2021 and later crashed 93.97% in 2024.
  • Year by year, Cash & Equivalents stood at $77.3 million in 2021, then crashed by 48.56% to $39.7 million in 2022, then crashed by 50.59% to $19.6 million in 2023, then crashed by 93.97% to $1.2 million in 2024, then rose by 26.58% to $1.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for PAVM at $1.5 million in Q4 2025, $3.1 million in Q3 2025, and $4.0 million in Q2 2025.